Claritus Pharmaceuticals Inc. (CLAZF)

[StockWatch45]

So it appears the deal being worked on is simply one to license the GVHD program as opposed to an outright sale of the company - which they say they anticipate happening in Q1 - essentially the next 100 days.

I wonder how big of a deal is contemplated? The company currently owes the Talent partners about $2M and this debenture appears to be another $475k or so for a total of roughly $2.5M needed to handle those two issues,. Additionally, they will need enough cash to get the Phase III double blind trial completed and the FDA approval over the line, plus more cash for funding the company's expenses and leaving them with some actual cash on hand.

Its getting interesting!